Accelerating Discovery Across Complex Disease Areas

Successful drug discovery starts with a deep understanding of disease biology. ChemPartner provides integrated preclinical research and drug discovery support across multiple therapeutic areas, helping biopharma and biotechnology organizations translate scientific insights into development-ready programs.

The Scientific Depth to Move Programs Forward

Our multidisciplinary teams combine discovery biology, pharmacology, medicinal chemistry, biologics, DMPK, toxicology, pathology, structural biology, and development expertise to support programs from target identification and validation through IND-enabling studies.

Whether you are advancing a first-in-class therapy, optimizing a lead candidate, or evaluating a novel modality, ChemPartner delivers the scientific capabilities needed to move programs forward with confidence.

ChemPartner brings together disease-specific knowledge, translational models, and modality expertise to accelerate decision-making throughout discovery.

Oncology & Immuno-Oncology

Our oncology experts leverage translational tumor models, biomarker strategies, immune profiling, and advanced pharmacology platforms to help evaluate efficacy, mechanism of action, and clinical relevance. Programs can be supported through CDX, PDX, syngeneic, and humanized models, alongside biologics discovery, antibody engineering, ADC development, and small-molecule research.

Key Focus Areas

Immunology & Inflammation

ChemPartner integrates in vitro, ex vivo, and in vivo immunology platforms to investigate adaptive and innate immune mechanisms, cytokine signaling pathways, immune-cell function, and translational biomarkers. Our teams help connect target biology to therapeutic outcomes through robust disease-relevant models and assay systems.

Key Focus Areas

Neuroscience

From target validation through efficacy assessment, ChemPartner provides integrated neuroscience capabilities including CNS pharmacology, electrophysiology, behavioral studies, biomarker analysis, pathology, and structural biology. Our scientists help generate the data needed to evaluate target engagement and therapeutic potential across neurological disorders.

Key Focus Areas

Metabolic Diseases

ChemPartner works across obesity, metabolic dysfunction, lipid disorders, and related disease areas, combining efficacy models with DMPK, bioanalysis, formulation, and ADME services. Our integrated approach helps teams understand pharmacological activity, exposure-response relationships, and translational potential.

Key Focus Areas

Cardiovascular

ChemPartner supports cardiovascular research across vascular biology, cardiac function, thrombosis, and related disease areas, combining relevant efficacy models with DMPK, bioanalysis, formulation, and ADME services. Our integrated approach helps teams evaluate pharmacological activity, exposure–response relationships, and translational potential.

Key Focus Areas

Infectious Diseases

ChemPartner supports anti-infective discovery across bacterial, viral, and host-directed programs, combining pathogen-focused assays and disease models with DMPK, bioanalysis, formulation, and ADME services. Our integrated approach helps teams assess antimicrobial activity, host–pathogen interactions, exposure–response relationships, and translational potential.

Key Focus Areas

Integrated Platforms Supporting Every Therapeutic Area

Drug discovery rarely fits neatly into a single disease category. That’s why every therapeutic-area program at ChemPartner is backed by a broad range of scientific platforms that can be deployed as programs evolve.

Biologics & Advanced Therapeutics

Support for biologics discovery, antibody discovery, antibody engineering, protein science, structural biology, and antibody-drug conjugate (ADC) development enables seamless progression from concept to candidate.

Medicinal Chemistry & Emerging Modalities

Our chemistry teams provide expertise in medicinal chemistry, peptide therapeutics, PROTAC development, oligonucleotide research, and other advanced modalities aligned with specific biological targets and therapeutic goals.

ADME, DMPK, Toxicology & Pathology

Virtual screening, de novo design, scaffold hopping, ADMET prediction, FEP, and retrosynthesis.aIntegrated preclinical development capabilities include in vitro ADME, DMPK, Met ID, bioanalysis, formulation development, exploratory toxicology, and histopathology to support informed program decisions and reduce development risk.

Frequently asked questions

What therapeutic areas does ChemPartner support?

ChemPartner provides integrated drug discovery and preclinical research support across Oncology & Immuno-Oncology, Immunology & Inflammation, Neuroscience, Metabolic Diseases, Cardiovascular Diseases, and Infectious Diseases. Each therapeutic area is supported by specialized scientific teams, translational models, and modality-specific expertise designed to accelerate research and development.

Can ChemPartner support programs that span multiple therapeutic areas?